false2025Q30000746598July 31http://fasb.org/us-gaap/2025#OtherLongTermDebtNoncurrenthttp://fasb.org/us-gaap/2025#OtherLongTermDebtNoncurrenthttp://fasb.org/us-gaap/2025#OtherLongTermDebtNoncurrenthttp://fasb.org/us-gaap/2025#OtherLongTermDebtNoncurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesutr:Rate00007465982024-08-012025-04-300000746598us-gaap:NonvotingCommonStockMember2025-05-140000746598us-gaap:CommonClassBMember2025-05-1400007465982025-04-3000007465982024-07-310000746598us-gaap:NonvotingCommonStockMember2025-04-300000746598us-gaap:NonvotingCommonStockMember2024-07-310000746598us-gaap:CommonClassBMember2024-07-310000746598us-gaap:CommonClassBMember2025-04-3000007465982025-02-012025-04-3000007465982024-02-012024-04-3000007465982023-08-012024-04-300000746598us-gaap:RetainedEarningsMember2024-02-012024-04-300000746598us-gaap:NonvotingCommonStockMember2025-02-012025-04-300000746598us-gaap:NonvotingCommonStockMember2024-02-012024-04-300000746598us-gaap:NonvotingCommonStockMember2024-08-012025-04-300000746598us-gaap:NonvotingCommonStockMember2023-08-012024-04-300000746598us-gaap:CommonClassBMember2025-02-012025-04-300000746598us-gaap:CommonClassBMember2024-02-012024-04-300000746598us-gaap:CommonClassBMember2024-08-012025-04-300000746598us-gaap:CommonClassBMember2023-08-012024-04-300000746598us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-02-012025-04-300000746598us-gaap:CommonStockMember2025-01-310000746598us-gaap:AdditionalPaidInCapitalMember2025-01-310000746598us-gaap:RetainedEarningsMember2025-01-310000746598us-gaap:TreasuryStockCommonMember2025-01-310000746598us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-3100007465982025-01-310000746598us-gaap:AdditionalPaidInCapitalMember2025-02-012025-04-300000746598us-gaap:TreasuryStockCommonMember2025-02-012025-04-300000746598us-gaap:NonvotingCommonStockMemberus-gaap:RetainedEarningsMember2025-02-012025-04-300000746598us-gaap:CommonClassBMemberus-gaap:RetainedEarningsMember2025-02-012025-04-300000746598us-gaap:CommonStockMember2025-04-300000746598us-gaap:AdditionalPaidInCapitalMember2025-04-300000746598us-gaap:RetainedEarningsMember2025-04-300000746598us-gaap:TreasuryStockCommonMember2025-04-300000746598us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-300000746598us-gaap:CommonStockMember2024-07-310000746598us-gaap:AdditionalPaidInCapitalMember2024-07-310000746598us-gaap:RetainedEarningsMember2024-07-310000746598us-gaap:TreasuryStockCommonMember2024-07-310000746598us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-310000746598us-gaap:RetainedEarningsMember2024-08-012025-04-300000746598us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-08-012025-04-300000746598us-gaap:AdditionalPaidInCapitalMember2024-08-012025-04-300000746598us-gaap:TreasuryStockCommonMember2024-08-012025-04-300000746598us-gaap:NonvotingCommonStockMemberus-gaap:RetainedEarningsMember2024-08-012025-04-300000746598us-gaap:CommonClassBMemberus-gaap:RetainedEarningsMember2024-08-012025-04-300000746598us-gaap:CommonStockMember2024-01-310000746598us-gaap:AdditionalPaidInCapitalMember2024-01-310000746598us-gaap:RetainedEarningsMember2024-01-310000746598us-gaap:TreasuryStockCommonMember2024-01-310000746598us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-3100007465982024-01-310000746598us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-02-012024-04-300000746598us-gaap:AdditionalPaidInCapitalMember2024-02-012024-04-300000746598us-gaap:TreasuryStockCommonMember2024-02-012024-04-300000746598us-gaap:NonvotingCommonStockMemberus-gaap:RetainedEarningsMember2024-02-012024-04-300000746598us-gaap:CommonClassBMemberus-gaap:RetainedEarningsMember2024-02-012024-04-300000746598us-gaap:CommonStockMember2024-04-300000746598us-gaap:AdditionalPaidInCapitalMember2024-04-300000746598us-gaap:RetainedEarningsMember2024-04-300000746598us-gaap:TreasuryStockCommonMember2024-04-300000746598us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-3000007465982024-04-300000746598us-gaap:CommonStockMember2023-07-310000746598us-gaap:AdditionalPaidInCapitalMember2023-07-310000746598us-gaap:RetainedEarningsMember2023-07-310000746598us-gaap:TreasuryStockCommonMember2023-07-310000746598us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-3100007465982023-07-310000746598us-gaap:RetainedEarningsMember2023-08-012024-04-300000746598us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-08-012024-04-300000746598us-gaap:AdditionalPaidInCapitalMember2023-08-012024-04-300000746598us-gaap:TreasuryStockCommonMember2023-08-012024-04-300000746598us-gaap:NonvotingCommonStockMemberus-gaap:RetainedEarningsMember2023-08-012024-04-300000746598us-gaap:CommonClassBMemberus-gaap:RetainedEarningsMember2023-08-012024-04-300000746598us-gaap:TradeNamesMember2025-04-300000746598us-gaap:TradeNamesMember2024-07-310000746598us-gaap:CustomerRelationshipsMember2025-04-300000746598us-gaap:CustomerRelationshipsMember2024-07-310000746598us-gaap:TechnologyBasedIntangibleAssetsMember2025-04-300000746598us-gaap:TechnologyBasedIntangibleAssetsMember2024-07-310000746598us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-07-310000746598us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-07-310000746598us-gaap:AccumulatedTranslationAdjustmentMember2024-07-310000746598us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-08-012025-04-300000746598us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-08-012025-04-300000746598us-gaap:AccumulatedTranslationAdjustmentMember2024-08-012025-04-300000746598us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-04-300000746598us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2025-04-300000746598us-gaap:AccumulatedTranslationAdjustmentMember2025-04-300000746598us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-07-310000746598us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-07-310000746598us-gaap:AccumulatedTranslationAdjustmentMember2023-07-310000746598us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-08-012024-04-300000746598us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-08-012024-04-300000746598us-gaap:AccumulatedTranslationAdjustmentMember2023-08-012024-04-300000746598us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-04-300000746598us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-04-300000746598us-gaap:AccumulatedTranslationAdjustmentMember2024-04-300000746598srt:AmericasMemberbrc:AmericasAsiaMember2025-02-012025-04-300000746598srt:AmericasMemberbrc:AmericasAsiaMember2024-02-012024-04-300000746598srt:AmericasMemberbrc:AmericasAsiaMember2024-08-012025-04-300000746598srt:AmericasMemberbrc:AmericasAsiaMember2023-08-012024-04-300000746598srt:AsiaMemberbrc:AmericasAsiaMember2025-02-012025-04-300000746598srt:AsiaMemberbrc:AmericasAsiaMember2024-02-012024-04-300000746598srt:AsiaMemberbrc:AmericasAsiaMember2024-08-012025-04-300000746598srt:AsiaMemberbrc:AmericasAsiaMember2023-08-012024-04-300000746598brc:AmericasAsiaMember2025-02-012025-04-300000746598brc:AmericasAsiaMember2024-02-012024-04-300000746598brc:AmericasAsiaMember2024-08-012025-04-300000746598brc:AmericasAsiaMember2023-08-012024-04-300000746598us-gaap:EMEAMemberbrc:EuropeAustraliaMember2025-02-012025-04-300000746598us-gaap:EMEAMemberbrc:EuropeAustraliaMember2024-02-012024-04-300000746598us-gaap:EMEAMemberbrc:EuropeAustraliaMember2024-08-012025-04-300000746598us-gaap:EMEAMemberbrc:EuropeAustraliaMember2023-08-012024-04-300000746598country:AUbrc:EuropeAustraliaMember2025-02-012025-04-300000746598country:AUbrc:EuropeAustraliaMember2024-02-012024-04-300000746598country:AUbrc:EuropeAustraliaMember2024-08-012025-04-300000746598country:AUbrc:EuropeAustraliaMember2023-08-012024-04-300000746598brc:EuropeAustraliaMember2025-02-012025-04-300000746598brc:EuropeAustraliaMember2024-02-012024-04-300000746598brc:EuropeAustraliaMember2024-08-012025-04-300000746598brc:EuropeAustraliaMember2023-08-012024-04-300000746598us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel1Member2025-04-300000746598us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel1Member2024-07-310000746598us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel2Member2025-04-300000746598us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel2Member2024-07-310000746598us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2025-04-300000746598us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2024-07-310000746598us-gaap:DesignatedAsHedgingInstrumentMember2025-04-300000746598us-gaap:DesignatedAsHedgingInstrumentMember2024-07-310000746598us-gaap:NondesignatedMember2025-04-300000746598us-gaap:NondesignatedMember2024-07-310000746598us-gaap:NetInvestmentHedgingMember2025-04-300000746598us-gaap:NetInvestmentHedgingMember2024-07-310000746598us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-04-300000746598us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-04-300000746598us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-310000746598us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-310000746598us-gaap:ForeignLineOfCreditMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2025-04-300000746598us-gaap:ForeignLineOfCreditMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2024-07-310000746598us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2025-04-300000746598us-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2025-04-300000746598us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2024-07-310000746598us-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2024-07-310000746598us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2025-04-300000746598us-gaap:OtherCurrentLiabilitiesMember2025-04-300000746598us-gaap:ForeignLineOfCreditMember2025-04-300000746598us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-07-310000746598us-gaap:OtherCurrentLiabilitiesMember2024-07-310000746598us-gaap:ForeignLineOfCreditMember2024-07-310000746598brc:GravotechAcquisitionMember2024-08-012025-04-300000746598brc:GravotechAcquisitionMember2024-08-010000746598brc:GravotechAcquisitionMemberbrc:AmericasAsiaMember2024-08-010000746598brc:GravotechAcquisitionMemberbrc:EuropeAustraliaMember2024-08-010000746598brc:GravotechAcquisitionMember2025-02-012025-04-300000746598brc:GravotechAcquisitionMember2024-02-012024-04-300000746598brc:GravotechAcquisitionMember2023-08-012024-04-300000746598brc:ABRAcquisitionMember2024-08-012025-04-300000746598brc:ABRAcquisitionMemberbrc:AmericasAsiaMember2024-10-010000746598brc:ABRAcquisitionMember2024-10-010000746598brc:MicrofluidicSolutionsAcquisitionMember2024-08-012025-04-300000746598brc:MicrofluidicSolutionsAcquisitionMember2025-04-010000746598brc:O2025Q3DividendsMemberus-gaap:SubsequentEventMember2025-05-152025-05-150000746598brc:O2025Q3DividendsMemberus-gaap:SubsequentEventMember2025-05-150000746598brc:O2025Q3DividendsMemberus-gaap:SubsequentEventMember2025-07-312025-07-310000746598brc:O2025Q3DividendsMemberus-gaap:SubsequentEventMember2025-07-102025-07-10
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended April 30, 2025
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period from                     to                     
Commission File Number 1-14959
BRADY CORPORATION
(Exact name of registrant as specified in its charter)
Wisconsin 39-0178960
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
6555 West Good Hope Road
Milwaukee, Wisconsin 53223
(Address of principal executive offices and zip code)
(414) 358-6600
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Class A Nonvoting Common Stock, par value $0.01 per shareBRCNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes     No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes    No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer Emerging growth company
Non-accelerated filer Smaller reporting company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   No   
As of May 14, 2025, there were 43,776,968 outstanding shares of Class A Nonvoting Common Stock and 3,538,628 shares of Class B Voting Common Stock. The Class B Voting Common Stock, all of which is held by affiliates of the Registrant, is the only voting stock.


Table of Contents
INDEX
 
 Page
2

Table of Contents
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

BRADY CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in Thousands)

April 30, 2025July 31, 2024
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents$152,154 $250,118 
Accounts receivable, net of allowance for credit losses of $8,967 and $6,749, respectively
224,358 185,486 
Inventories189,991 152,729 
Prepaid expenses and other current assets15,399 11,382 
Total current assets581,902 599,715 
Property, plant and equipment—net219,082 195,758 
Goodwill682,554 589,611 
Other intangible assets111,685 51,839 
Deferred income taxes20,583 15,596 
Operating lease assets58,118 38,504 
Other assets24,191 24,546 
Total$1,698,115 $1,515,569 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$99,754 $84,691 
Accrued compensation and benefits87,506 77,954 
Taxes, other than income taxes19,711 14,061 
Accrued income taxes2,976 7,424 
Current operating lease liabilities15,030 13,382 
Other current liabilities86,809 67,170 
Total current liabilities311,786 264,682 
Long-term debt102,819 90,935 
Long-term operating lease liabilities43,772 25,342 
Other liabilities72,185 67,952 
Total liabilities530,562 448,911 
Stockholders’ equity:
Class A nonvoting common stock—Issued 51,261,487 shares, and outstanding 43,774,580 and 44,042,462 shares, respectively
513 513 
Class B voting common stock—Issued and outstanding, 3,538,628 shares
35 35 
Additional paid-in capital357,545 353,654 
Retained earnings1,279,168 1,174,025 
Treasury stock—7,486,907 and 7,219,025 shares, respectively, of Class A nonvoting common stock, at cost
(375,974)(351,947)
Accumulated other comprehensive loss(93,734)(109,622)
Total stockholders’ equity1,167,553 1,066,658 
Total$1,698,115 $1,515,569 

See Notes to Condensed Consolidated Financial Statements.
3

Table of Contents
BRADY CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Dollars in Thousands, Except Per Share Amounts, Unaudited)

Three months ended April 30,Nine months ended April 30,
 2025202420252024
Net sales$382,590 $343,384 $1,116,330 $997,991 
Cost of goods sold187,531 166,357 555,739 487,162 
Gross margin195,059 177,027 560,591 510,829 
Operating expenses:
Research and development19,191 17,681 56,835 50,215 
Selling, general and administrative108,678 95,803 326,410 283,415 
Total operating expenses127,869 113,484 383,245 333,630 
Operating income 67,190 63,543 177,346 177,199 
Other (expense) income:
Investment and other (expense) income(509)1,596 2,850 4,718 
Interest expense(936)(728)(3,604)(2,284)
Income before income taxes65,745 64,411 176,592 179,633 
Income tax expense13,482 13,521 37,212 37,874 
Net income$52,263 $50,890 $139,380 $141,759 
Net income per Class A Nonvoting Common Share:
Basic$1.10 $1.06 $2.92 $2.94 
Diluted$1.09 $1.05 $2.89 $2.91 
Net income per Class B Voting Common Share:
Basic$1.10 $1.06 $2.90 $2.92 
Diluted$1.09 $1.05 $2.88 $2.90 
Weighted average common shares outstanding:
Basic47,644 48,004 47,743 48,294 
Diluted48,066 48,386 48,196 48,640 

See Notes to Condensed Consolidated Financial Statements.
4

Table of Contents
BRADY CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Dollars in Thousands, Unaudited)

Three months ended April 30,Nine months ended April 30,
 2025202420252024
Net income$52,263 $50,890 $139,380 $141,759 
Other comprehensive income (loss):
Foreign currency translation adjustments38,161 (6,537)16,902 (12,310)
Cash flow hedges:
Net (loss) gain recognized in other comprehensive income (loss)(423)447 (826)1,236 
Reclassification adjustment for losses (gains) included in net income210 (173)209 (1,712)
(213)274 (617)(476)
Pension and other post-retirement benefits actuarial gain amortization(152)(152)(454)(454)
Other comprehensive income (loss), before tax37,796 (6,415)15,831 (13,240)
Income tax benefit (expense) related to items of other comprehensive income (loss)297 (51)57 (106)
Other comprehensive income (loss), net of tax38,093 (6,466)15,888 (13,346)
Comprehensive income$90,356 $44,424 $155,268 $128,413 

See Notes to Condensed Consolidated Financial Statements.
5

Table of Contents
BRADY CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Dollars in Thousands, Unaudited)
Three months ended April 30, 2025
Common StockAdditional
 Paid-In Capital
Retained EarningsTreasury StockAccumulated Other Comprehensive LossTotal Stockholders' Equity
Balances at January 31, 2025$548 $356,531 $1,238,275 $(343,059)$(131,827)$1,120,468 
Net income— — 52,263 — — 52,263 
Other comprehensive income, net of tax— — — — 38,093 38,093 
Issuance of shares of Class A Common Stock under stock plan— (755)— 415 — (340)
Stock-based compensation expense— 1,769 — — — 1,769 
Repurchase of shares of Class A Common Stock, including excise taxes— — — (33,330)— (33,330)
Cash dividends on Common Stock:
Class A — $0.2400 per share
— — (10,521)— — (10,521)
Class B — $0.2400 per share
— — (849)— — (849)
Balances at April 30, 2025$548 $357,545 $1,279,168 $(375,974)$(93,734)$1,167,553 
Nine months ended April 30, 2025
Common StockAdditional
 Paid-In Capital
Retained EarningsTreasury StockAccumulated Other Comprehensive LossTotal Stockholders' Equity
Balances at July 31, 2024$548 $353,654 $1,174,025 $(351,947)$(109,622)$1,066,658 
Net income— — 139,380 — — 139,380 
Other comprehensive income, net of tax— — — — 15,888 15,888 
Issuance of shares of Class A Common Stock under stock plan— (6,061)— 9,303 — 3,242 
Tax benefit and withholdings from deferred compensation distributions— 190 — — — 190 
Stock-based compensation expense— 9,762 — — — 9,762 
Repurchase of shares of Class A Common Stock, including excise taxes— — — (33,330)— (33,330)
Cash dividends on Common Stock:
Class A — $0.7200 per share
— — (31,749)— — (31,749)
Class B — $0.7034 per share
— — (2,488)— — (2,488)
Balances at April 30, 2025$548 $357,545 $1,279,168 $(375,974)$(93,734)$1,167,553 

6

Table of Contents
Three months ended April 30, 2024
Common StockAdditional
 Paid-In Capital
Retained EarningsTreasury StockAccumulated Other Comprehensive LossTotal Stockholders' Equity
Balances at January 31, 2024$548 $353,794 $1,090,045 $(305,714)$(99,941)$1,038,732 
Net income— — 50,890 — — 50,890 
Other comprehensive loss, net of tax— — — — (6,466)(6,466)
Issuance of shares of Class A Common Stock under stock plan— (521)— 436 — (85)
Stock-based compensation expense— 1,159 — — — 1,159 
Repurchase of shares of Class A Common Stock, including excise taxes— — — (50,932)— (50,932)
Cash dividends on Common Stock:
Class A — $0.2350 per share
— — (10,364)— — (10,364)
Class B — $0.2350 per share
— — (832)— — (832)
Balances at April 30, 2024$548 $354,432 $1,129,739 $(356,210)$(106,407)$1,022,102 
Nine months ended April 30, 2024
Common StockAdditional
 Paid-In Capital
Retained EarningsTreasury StockAccumulated Other Comprehensive LossTotal Stockholders' Equity
Balances at July 31, 2023$548 $351,771 $1,021,870 $(290,209)$(93,061)$990,919 
Net income— — 141,759 — — 141,759 
Other comprehensive loss, net of tax— — — — (13,346)(13,346)
Issuance of shares of Class A Common Stock under stock plan— (3,910)— 6,829 — 2,919 
Tax benefit and withholdings from deferred compensation distributions— 149 — — — 149 
Stock-based compensation expense— 6,422 — — — 6,422 
Repurchase of shares of Class A Common Stock, including excise taxes— — — (72,830)— (72,830)
Cash dividends on Common Stock:
Class A — $0.7050 per share
— — (31,454)— — (31,454)
Class B — $0.6884 per share
— — (2,436)— — (2,436)
Balances at April 30, 2024$548 $354,432 $1,129,739 $(356,210)$(106,407)$1,022,102 

7

Table of Contents
BRADY CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in Thousands, Unaudited)

Nine months ended April 30,
 20252024
Operating activities:
Net income$139,380 $141,759 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization30,279 22,406 
Stock-based compensation expense9,762 6,422 
Deferred income taxes(6,038)(6,902)
Other(181)1,358 
Changes in operating assets and liabilities:
Accounts receivable(6,869)(15,915)
Inventories(8,209)20,861 
Prepaid expenses and other assets(3,754)(1,849)
Accounts payable and accrued liabilities(26,415)7,347 
Income taxes(5,081)(4,393)
Net cash provided by operating activities122,874 171,094 
Investing activities:
Purchases of property, plant and equipment(18,685)(69,157)
Acquisition of businesses, net of cash acquired(147,248) 
Other854 (1,174)
Net cash used in investing activities(165,079)(70,331)
Financing activities:
Payment of dividends(34,237)(33,890)
Proceeds from exercise of stock options5,759 5,583 
Payments for employee taxes withheld from stock-based awards(2,518)(2,664)
Purchase of treasury stock(33,155)(72,225)
Proceeds from borrowing on credit agreement206,249 111,790 
Repayment of borrowing on credit agreement(194,365)(97,732)
Other190 149 
Net cash used in financing activities(52,077)(88,989)
Effect of exchange rate changes on cash and cash equivalents(3,682)(2,848)
Net (decrease) increase in cash and cash equivalents(97,964)8,926 
Cash and cash equivalents, beginning of period250,118 151,532 
Cash and cash equivalents, end of period$152,154 $160,458 

See Notes to Condensed Consolidated Financial Statements.
8

Table of Contents
BRADY CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Nine Months Ended April 30, 2025
(Unaudited)
(In thousands, except share and per share amounts)
NOTE A — Basis of Presentation
The condensed consolidated financial statements included herein have been prepared by Brady Corporation and subsidiaries (the “Company,” “Brady,” “we,” or “our”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of the Company, the foregoing statements contain all adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial position of the Company as of April 30, 2025 and July 31, 2024, its results of operations and comprehensive income for the three and nine months ended April 30, 2025 and 2024, and cash flows for the nine months ended April 30, 2025 and 2024. The condensed consolidated balance sheet as of July 31, 2024 has been derived from the audited consolidated financial statements as of that date. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts therein. Due to the inherent uncertainty involved in making estimates, actual results in future periods may differ from the estimates.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to rules and regulations of the Securities and Exchange Commission. Accordingly, the condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statement presentation. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2024.

NOTE B — New Accounting Pronouncements
Standards not yet adopted
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The guidance requires expanded interim and annual disclosures of segment information including the disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within segment profit and loss. The guidance is effective for the Company's fiscal 2025 Form 10-K and interim periods thereafter. The Company is currently assessing its segment information disclosures in connection with the adoption of ASU 2023-07.
In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The guidance requires expanded annual disclosures including the standardization and disaggregation of income tax rate reconciliation categories and the amount of income taxes paid by jurisdiction. The guidance is effective for the Company’s fiscal 2026 Form 10-K. The Company is currently assessing its income tax disclosures in connection with the adoption of ASU 2023-09.
In November 2024, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” The guidance requires expanded interim and annual disclosures of expense information including the amounts of inventory purchases, employee compensation, depreciation, amortization, and depletion within commonly presented expense captions during the period. The guidance is effective for the Company's fiscal 2028 Form 10-K and interim periods thereafter. The Company is currently evaluating the ASU to determine its impact on the Company's disclosures.
9

Table of Contents
NOTE C — Additional Balance Sheet Information
Inventories
Inventories consisted of the following as of April 30, 2025 and July 31, 2024:
 April 30, 2025July 31, 2024
Finished products$104,559 $89,430 
Work-in-process29,332 24,601 
Raw materials and supplies56,100 38,698 
Total inventories$189,991 $152,729 
Property, plant and equipment
Property, plant and equipment is presented net of accumulated depreciation in the amount of $309,349 and $304,199 as of April 30, 2025 and July 31, 2024, respectively.

NOTE D — Other Intangible Assets
Other intangible assets as of April 30, 2025 and July 31, 2024 consisted of the following: 
 April 30, 2025July 31, 2024
Weighted Average Amortization Period (Years)Gross Carrying AmountAccumulated AmortizationNet Book ValueWeighted Average Amortization Period (Years)Gross Carrying AmountAccumulated AmortizationNet Book Value
Amortized other intangible assets:
Tradenames2$911 $(342)$569 3$600 $(600)$ 
Customer relationships8126,148 (34,778)91,370 964,430 (23,279)41,151 
Technology521,500 (9,411)12,089 59,300 (6,182)3,118 
Unamortized other intangible assets:
TradenamesN/A7,657 — 7,657 N/A7,570 — 7,570 
Total$156,216 $(44,531)$111,685 $81,900 $(30,061)$51,839 
The change in the gross carrying amount of other intangible assets as of April 30, 2025 compared to July 31, 2024 was primarily due to the acquisitions of Gravotech Holding (“Gravotech”), American Barcode and RFID Incorporated (“AB&R”), and the Microfluidic Solutions business unit of Funai Electric Co., Ltd. (“Microfluidic Solutions”) completed during the nine months ended April 30, 2025 and to a lesser extent, the effect of currency fluctuations. Refer to Note N, “Acquisitions,” for additional information on intangible assets acquired.
Amortization expense on intangible assets was $4,754 and $2,365 for the three months ended April 30, 2025 and 2024, respectively, and $14,138 and $7,084 for the nine months ended April 30, 2025 and 2024, respectively.

NOTE E — Leases
The Company leases certain manufacturing facilities, warehouse and office spaces, and vehicles accounted for as operating leases. Lease terms typically range from one year to ten years. As of April 30, 2025, the Company did not have any finance leases.
Operating lease expense was $4,714 and $3,688 for the three months ended April 30, 2025 and 2024, respectively, and $13,988 and $11,557 for the nine months ended April 30, 2025 and 2024, respectively, which was recognized in either “Cost of goods sold” or “Selling, general and administrative” expenses in the condensed consolidated statements of income, based on the nature of the lease. Short-term lease expense, variable lease expenses, and sublease income were immaterial to the condensed consolidated statements of income for the three and nine months ended April 30, 2025 and 2024.
10

Table of Contents
Supplemental cash flow information related to the Company's operating leases for the nine months ended April 30, 2025 and 2024 was as follows:
Nine months ended April 30,
20252024
Operating cash outflows from operating leases$13,780 $12,441 
Operating lease assets obtained in exchange for new operating lease liabilities (1)
30,964 8,903 
(1) Includes new leases and remeasurements or modifications of existing leases.

NOTE F — Accumulated Other Comprehensive Loss
Other comprehensive income (loss) consists of foreign currency translation adjustments, which includes net investment hedges and long-term intercompany loan translation adjustments, unrealized gains and losses from cash flow hedges, and the unamortized gain on post-retirement plans, net of their related tax effects.
The following table illustrates the changes in the balances of each component of accumulated other comprehensive loss, net of tax, for the nine months ended April 30, 2025:
Unrealized loss on cash flow hedgesUnamortized gain on post-retirement plansForeign currency translation adjustmentsAccumulated other comprehensive loss
Beginning balance, July 31, 2024$(149)$462 $(109,935)$(109,622)
Other comprehensive (loss) income before reclassification(716) 16,902 16,186 
Amounts reclassified from accumulated other comprehensive loss156 (454) (298)
Ending balance, April 30, 2025$(709)$8 $(93,033)$(93,734)
The decrease in accumulated other comprehensive loss as of April 30, 2025 compared to July 31, 2024 was primarily due to the depreciation of the U.S. dollar against certain other currencies during the nine-month period.
The changes in accumulated other comprehensive loss by component, net of tax, for the nine months ended April 30, 2024 were as follows:
Unrealized gain on cash flow hedgesUnamortized gain on post-retirement plansForeign currency translation adjustmentsAccumulated other comprehensive loss
Beginning balance, July 31, 2023$1,641 $756 $(95,458)$(93,061)
Other comprehensive income (loss) before reclassification702  (12,310)(11,608)
Amounts reclassified from accumulated other comprehensive loss(1,284)(454) (1,738)
Ending balance, April 30, 2024$1,059 $302 $(107,768)$(106,407)
The increase in accumulated other comprehensive loss as of April 30, 2024 compared to July 31, 2023 was primarily due to the appreciation of the U.S. dollar against certain other currencies during the nine-month period.
Of the amounts reclassified from accumulated other comprehensive loss during the nine months ended April 30, 2025 and 2024, unrealized (losses) gains on cash flow hedges were reclassified to “Cost of goods sold” and unamortized gains on post-retirement plans were reclassified into “Investment and other (expense) income” on the condensed consolidated statements of income.
The following table illustrates the income tax benefit (expense) on the components of other comprehensive income (loss) for the three and nine months ended April 30, 2025 and 2024:
Three months ended April 30,Nine months ended April 30,
2025202420252024
Income tax benefit (expense) related to items of other comprehensive loss:
Cash flow hedges$297 $(51)$57 $(106)

11

Table of Contents
NOTE G — Revenue Recognition
The Company recognizes revenue when control of the product or service transfers to the customer at an amount that represents the consideration expected to be received in exchange for those products and services. The Company’s revenues are primarily from the sale of identification solutions and workplace safety products that are shipped and billed to customers. All revenue is from contracts with customers and is included in “Net sales” on the condensed consolidated statements of income. See Note H, “Segment Information,” for the Company’s disaggregated revenue disclosure.
The Company offers extended warranty coverage that is included in the sales price of certain products, which it accounts for as service warranties. The Company accounts for the deferred revenue associated with extended service warranties as a contract liability. The balance of contract liabilities associated with service warranty performance obligations was $2,986 and $2,947 as of April 30, 2025 and July 31, 2024, respectively. The current portion and non-current portion of contract liabilities are included in “Other current liabilities” and “Other liabilities,” respectively, on the condensed consolidated balance sheets. The Company recognized revenue of $343 and $325 during the three months ended April 30, 2025 and 2024, respectively, and $1,021 and $960 during the nine months ended April 30, 2025 and 2024, respectively, that was included in the contract liability balance at the beginning of the respective period from the amortization of extended service warranties. Of the contract liability balance outstanding at April 30, 2025, the Company expects to recognize 12% by the end of fiscal 2025, an additional 38% by the end of fiscal 2026, and the remaining balance thereafter. 

NOTE H — Segment Information
The Company is organized and managed within two regions: Americas & Asia and Europe & Australia, which are the reportable segments.
The following is a summary of net sales by segment and geographic region for the three and nine months ended April 30, 2025 and 2024:
Three months ended April 30,Nine months ended April 30,
2025202420252024
Net sales:
Americas & Asia
Americas$219,913 $200,602 $636,493 $582,864 
Asia33,739 24,164 96,433 75,171 
Total$253,652 $224,766 $732,926 $658,035 
Europe & Australia
Europe$115,715 $104,925 $342,345 $299,629 
Australia13,223 13,693 41,059 40,327 
Total$128,938 $118,618 $383,404 $339,956 
Total Company$382,590 $343,384 $1,116,330 $997,991 
The following is a summary of segment profit for the three and nine months ended April 30, 2025 and 2024:
Three months ended April 30,Nine months ended April 30,
 2025202420252024
Segment profit:
Americas & Asia$57,164 $49,697 $158,148 $143,489 
Europe & Australia17,478 19,537 41,872 51,335 
Total profit from reportable segments$74,642 $69,234 $200,020 $194,824 
12

Table of Contents
Total profit from reportable segments is a measure of operating income that excludes administrative costs related to corporate functions that are otherwise included in the Company's operating income. The following is a reconciliation of total profit from reportable segments to income before income taxes for the three and nine months ended April 30, 2025 and 2024:
Three months ended April 30,Nine months ended April 30,
 2025202420252024
Total profit from reportable segments$74,642 $69,234 $200,020 $194,824 
Unallocated amounts:
Administrative costs(7,452)(5,691)(22,674)(17,625)
Investment and other (expense) income(509)1,596 2,850 4,718 
Interest expense(936)(728)(3,604)(2,284)
Income before income taxes$65,745 $64,411 $176,592 $179,633 

NOTE I — Net Income per Common Share
Reconciliations of the numerator and denominator of the basic and diluted per share computations for the Company’s Class A and Class B common stock are summarized as follows:
Three months ended April 30,Nine months ended April 30,
 2025202420252024
Numerator (in thousands):
Net income (Numerator for basic and diluted income per Class A Nonvoting Common Share)$52,263 $50,890 $139,380 $141,759 
Less:
Preferential dividends  (736)(748)
Preferential dividends on dilutive stock options  (8)(5)
Numerator for basic and diluted income per Class B Voting Common Share$52,263 $50,890 $138,636 $141,006 
Denominator (in thousands):
Denominator for basic income per share for both Class A and Class B47,644 48,004 47,743 48,294 
Plus: Effect of dilutive equity awards422 382 453 346 
Denominator for diluted income per share for both Class A and Class B48,066 48,386 48,196 48,640 
Net income per Class A Nonvoting Common Share:
Basic$1.10 $1.06 $2.92 $2.94 
Diluted$1.09 $1.05 $2.89 $2.91 
Net income per Class B Voting Common Share:
Basic$1.10 $1.06 $2.90 $2.92 
Diluted$1.09 $1.05 $2.88 $2.90 
Potentially dilutive securities attributable to outstanding stock options and restricted stock units were excluded from the calculation of diluted earnings per share where the combined exercise price and average unamortized fair value were greater than the average market price of the Company's Class A Nonvoting Common Stock because the effect would have been anti-dilutive. There were no anti-dilutive shares for the three months ended April 30, 2025. The amount of anti-dilutive shares were 47,409 for the three months ended April 30, 2024, and 5,759 and 136,919 for the nine months ended April 30, 2025 and 2024, respectively.

13

Table of Contents
NOTE J — Fair Value Measurements
In accordance with fair value accounting guidance, the Company determines fair value based on the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The inputs used to measure fair value are classified into the following hierarchy:
Level 1 — Unadjusted quoted prices in active markets for identical instruments that are accessible as of the reporting date.
Level 2 — Other significant pricing inputs that are either directly or indirectly observable.
Level 3 — Significant unobservable pricing inputs, which result in the use of management's own assumptions.
The following table summarizes the Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of April 30, 2025 and July 31, 2024:
 April 30, 2025July 31, 2024Fair Value Hierarchy
Assets:
Deferred compensation plan assets$18,485 $20,029 Level 1
Foreign exchange contracts50 137 Level 2
Liabilities:
Foreign exchange contracts407 730 Level 2
The following methods and assumptions were used to estimate the fair value of each class of financial instrument:
Deferred compensation plan assets: The Company’s deferred compensation investments consist of investments in mutual funds, which are included in “Other assets” on the condensed consolidated balance sheets. These investments were classified as Level 1 as the shares of these investments trade with sufficient frequency and volume to enable us to obtain pricing information on an ongoing basis.
Foreign exchange contracts: The Company’s foreign exchange contracts were classified as Level 2 as the fair value was based on the present value of the future cash flows using external models that use observable inputs, such as interest rates, yield curves and foreign exchange rates. See Note K, “Derivatives and Hedging Activities,” for additional information.
The fair values of cash and cash equivalents, accounts receivable, accounts payable, and other liabilities approximated carrying values due to their short-term nature.

NOTE K — Derivatives and Hedging Activities
The Company utilizes forward foreign exchange currency contracts to reduce the exchange rate risk of specific foreign currency denominated transactions. These contracts typically require the exchange of a foreign currency for U.S. dollars at a fixed rate on a future date, with maturities of less than 18 months, which qualify as cash flow hedges or net investment hedges under the accounting guidance for derivative instruments and hedging activities. The primary objective of the Company’s foreign currency exchange risk management program is to minimize the impact of currency movements due to transactions in other than the respective subsidiaries’ functional currency and to minimize the impact of currency movements on the Company’s net investment denominated in a currency other than the U.S. dollar. To achieve this objective, the Company hedges a portion of known exposures using forward foreign exchange currency contracts.
Main foreign currency exposures are related to transactions denominated in the British Pound, Euro, Canadian dollar, Australian dollar, Mexican Peso, Chinese Yuan, Malaysian Ringgit and Singapore dollar. Generally, these risk management transactions will involve the use of foreign currency derivatives to minimize the impact of currency movements on non-functional currency transactions.
The U.S. dollar equivalent notional amounts of outstanding forward exchange contracts were as follows:
April 30, 2025July 31, 2024
Designated as cash flow hedges$14,844 $59,207 
Non-designated hedges4,352 4,459 
Total foreign exchange contracts$19,196 $63,666 
14

Table of Contents
Cash Flow Hedges
The Company has designated a portion of its forward foreign exchange contracts as cash flow hedges and recorded these contracts at fair value on the condensed consolidated balance sheets. For these instruments, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (“OCI”) and reclassified into income in the same period or periods during which the hedged transaction affects income. As of April 30, 2025 and July 31, 2024, unrealized losses of $742 and $124 have been included in OCI, respectively.
Net Investment Hedges
The Company has designated certain third party foreign currency denominated debt borrowed under its credit agreement as net investment hedges. These debt obligations, denominated in Euros and British Pounds, were designated as net investment hedges to hedge portions of the Company's net investment in its European operations. The Company’s foreign currency denominated debt obligations are valued under a market approach using publicized spot prices, and the net gains or losses attributable to the changes in spot prices are recorded as cumulative translation within AOCI and are included in the foreign currency translation adjustments section of the condensed consolidated statements of comprehensive income. As of April 30, 2025 and July 31, 2024, the cumulative balances recognized in accumulated other comprehensive income were losses of $2,850 and $1,237, respectively, on any outstanding foreign currency denominated debt obligations.
The following table summarizes the amount of pre-tax gains and losses related to derivatives designated as hedging instruments:
Three months ended April 30,Nine months ended April 30,
  2025202420252024
(Losses) gains recognized in OCI:
Forward exchange contracts (cash flow hedges)$(423)$447 $(826)$1,236 
Foreign currency denominated debt (net investment hedges)(2,883)408 (1,613)947 
(Losses) gains reclassified from OCI into cost of goods sold
Forward exchange contracts (cash flow hedges)(210)173 (209)1,712 
Fair values of derivative instruments in the condensed consolidated balance sheets were as follows:
 April 30, 2025July 31, 2024
Prepaid expenses and other current assetsOther current liabilitiesLong-term obligationsPrepaid expenses and other current assetsOther current liabilitiesLong-term obligations
Derivatives designated as hedging instruments:
Foreign exchange contracts (cash flow hedges)$50 $406 $— $137 $726 $— 
Foreign currency denominated debt (net investment hedges)— — 34,633 — — 34,060 
Derivatives not designated as hedging instruments:
Foreign exchange contracts (non-designated hedges) 1 —  4 — 
Total derivative instruments$50 $407 $34,633 $137 $730 $34,060 

NOTE L — Income Taxes
The income tax rate for the three months ended April 30, 2025 and 2024 was 20.5% and 21.0%, respectively. The income tax rate for both of the nine months ended April 30, 2025 and 2024 was 21.1%.

15

Table of Contents
NOTE M — Contingencies
In the normal course of business, the Company is subject to a variety of investigations, claims, suits, and other legal proceedings, including but not limited to, intellectual property, employment, unclaimed property, tort, and breach of contract matters. Any legal proceedings are subject to inherent uncertainties, and these matters and their potential effects may change in the future. The Company records a liability for contingencies when a loss is deemed to be probable and the loss can be reasonably estimated. The Company currently believes that the outcomes of such proceedings will not have a material adverse impact on its business, financial position, results of operations or cash flows.

NOTE N — Acquisitions
On August 1, 2024, the Company acquired all of the outstanding shares of Gravotech. Headquartered in Lyon, France, Gravotech is a leader in the design, manufacture and distribution of innovative solutions for specialized engraving, marking and cutting, offering laser, mechanical engraving, scribing and dot peen capabilities across multiple industries. The acquisition of Gravotech expands the Company’s identification product offerings and research and development capabilities to include specialized direct part marking and engraving expertise. The acquisition was funded through cash on hand and borrowings under the Company’s existing credit agreement. Net sales and net loss attributable to Gravotech from the acquisition date through April 30, 2025 were $85,528 and $10,439, respectively. The net loss attributable to Gravotech is due to a non-recurring increase in cost of goods sold related to the fair value adjustment to inventory upon acquisition and amortization expense for intangible assets.
The preliminary purchase price allocation included goodwill of $69,936 of which $48,586 was assigned to the Americas & Asia segment and $21,350 was assigned to the Europe & Australia segment.
The following table summarizes the preliminary fair value of the assets acquired and liabilities assumed at the date of the acquisition:
Cash and cash equivalents$7,469 
Accounts receivable, net23,697 
Inventories21,190 
Prepaid expenses and other current assets549 
Property, plant and equipment — net2,472 
Goodwill69,936 
Other intangible assets64,099 
Operating lease assets6,800 
Other assets1,034 
Accounts payable(17,353)
Accrued compensation and benefits(9,106)
Taxes, other than income taxes(6,680)
Accrued income taxes(1,807)
Other current liabilities(17,688)
Operating lease liabilities(6,800)
Other liabilities(6,729)
Net assets acquired$131,083 
Less: cash acquired(7,469)
Fair value of total consideration$123,614 
The final purchase price allocation is subject to post-closing adjustments pursuant to the terms of the securities sale and purchase agreement, as well as the finalization of certain accounts, primarily intangible assets and deferred tax adjustments. The goodwill for this acquisition is not deductible for tax purposes.
16

Table of Contents
The following table presents the unaudited pro forma operating results of the Company for the three and nine months ended April 30, 2025 and 2024, reflecting the acquisition of Gravotech as if it had occurred at the beginning of fiscal year 2024. The unaudited pro forma operating results for the three and nine months ended April 30, 2025 do not contain any adjustments to the accompanying condensed consolidated financial statements. The unaudited pro forma operating results for the three and nine months ended April 30, 2024 include Gravotech’s normal operating results and pro forma adjustments to include cumulative expenses, net of tax, for the non-recurring fair value adjustment to inventory, amortization expense for acquired intangible assets and interest expense on acquisition-related debt. The unaudited pro forma operating results are presented for comparative purposes only and do not necessarily reflect future operating results or those that would have occurred had the acquisition been completed at the beginning of fiscal year 2024.
 Three months ended April 30,Nine months ended April 30,
2025202420252024
Net sales, pro forma$382,590 $371,732 $1,116,330 $1,085,253 
Net income, pro forma52,263 48,339 139,380 135,257 
On October 1, 2024, the Company acquired all of the outstanding shares of AB&R for $14,827, net of cash acquired. Based in Phoenix, Arizona, AB&R provides integrated solutions for asset tracking, inventory management, and workflow optimization using advanced identification and tracking technologies, including barcoding, radio frequency identification (“RFID”) and Internet of Things (“IoT”)-based systems. The acquisition was funded through cash on hand and borrowings under the Company’s existing credit agreement. The Company recorded its preliminary purchase price allocation during the first quarter of fiscal year 2025, based on its estimates of the fair value of the acquired assets and assumed liabilities at that time. The preliminary purchase price allocation included goodwill of $10,079, intangible assets of $4,600, and net tangible assets of $148. The goodwill for this acquisition is assigned to the Americas & Asia segment and is deductible for tax purposes. The final purchase price allocation is subject to post-closing adjustments and the finalization of certain intangible asset valuations and deferred tax adjustments, as well as potential contingent consideration subject to AB&R’s achievement of certain post-acquisition financial targets pursuant to the terms of the membership interest purchase agreement. Acquisition-related expenses of $305 were recognized in selling, general and administrative (“SG&A”) expenses during the nine months ended April 30, 2025. The accompanying condensed consolidated financial statements include the results of AB&R from the date of acquisition through April 30, 2025. Pro forma and other financial information are not presented for the AB&R acquisition because its impact on the Company's results of operation and financial position is immaterial.
On April 1, 2025, the Company acquired certain assets and liabilities representing the Microfluidic Solutions business unit of Funai Electric Co., Ltd., for $11,648. Headquartered in Lexington, Kentucky, with a manufacturing facility in Cebu, Philippines, Microfluidic Solutions specializes in the research, development and manufacturing of advanced inkjet microfluidic technologies. The acquisition was funded through cash on hand and borrowings under the Company’s existing credit agreement. The Company recorded its preliminary purchase price allocation during the third quarter of fiscal year 2025, based on its estimates of the fair value of the acquired assets and assumed liabilities at that time. The preliminary purchase price allocation included property, plant and equipment of $12,090, inventories of $3,028, other intangible assets of $1,544, accounts payable of $1,111, and other liabilities of $3,903. The final purchase price allocation is subject to post-closing adjustments and the finalization of certain tangible asset valuations, intangible asset valuations and deferred tax adjustments. The accompanying condensed consolidated financial statements include the results of Microfluidic Solutions from the date of acquisition through April 30, 2025. Pro forma and other financial information are not presented for the Microfluidic Solutions acquisition because its impact on the Company's results of operation and financial position is immaterial.

NOTE O — Subsequent Events
On May 15, 2025, the Board of Directors declared a quarterly cash dividend to shareholders of the Company’s Class A and Class B Common Stock of $0.24 per share payable on July 31, 2025, to shareholders of record at the close of business on July 10, 2025.

17

Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Brady Corporation is a global manufacturer and supplier of identification solutions and workplace safety products that identify and protect premises, products and people. The Company is organized and managed on a geographic basis with two reportable segments: Americas & Asia and Europe & Australia. This regional operating structure allows the Company to further integrate its businesses, support continued growth through the application of the best go-to-market strategies in key geographies, facilitate new product development within recent acquisitions and further simplify and scale the global business.
Within each of the reportable segments, the Company markets, sells and distributes a broad range of identification and safety products and solutions across the following primary product categories:

Safety and facility identification and protection, which includes safety signs, traffic signs and control products, floor-marking tape, pipe markers, labeling systems, spill control products, lockout/tagout devices, personal protection equipment, first aid products, and software and services for safety compliance auditing, procedures writing and training.
Product identification, which includes materials, printing systems, radio frequency identification (“RFID”) and barcode scanners for product identification, engraving equipment, brand protection labeling, work in process labeling, finished product identification, asset tracking labels, asset tags and industrial track and trace applications.
Wire identification, which includes handheld printers, wire markers, sleeves, and tags.
Healthcare identification, which includes wristbands, labels, printing systems, and other products used in hospital, laboratory, and other healthcare settings for tracking and improving the safety of patients.
People identification, which includes name tags, badges, lanyards, rigid card printing systems, and access control software.
The ability to provide customers with a broad range of proprietary, customized and diverse products for use in various applications across multiple industries and geographies, along with a commitment to quality and service, have made Brady a leader in many of its markets. Brady's long-term sales growth and profitability will depend not only on the overall economic environment and our ability to successfully navigate changes in the macro environment, but also on our ability to develop and market innovative products, deliver a high level of customer service, advance our digital capabilities, and continuously improve the efficiency of our global operations. Our strategy for growth includes an increased focus on certain industries and products, streamlining our product offerings, expanding into higher growth end-markets, intensifying efforts to leverage our diverse product portfolio and synergies across our business, improving the overall customer experience, developing technologically advanced, innovative, and proprietary products, and improving our digital capabilities.
The following are key initiatives supporting our strategy in fiscal 2025:
Investing in organic growth by enhancing our research and development process and utilizing customer feedback and observations to develop innovative new products that solve customer needs and improve environmental sustainability.
Providing the highest level of customer service by aligning with customers' preferred communications channels and leveraging technology to enhance the customer experience.
Expanding and enhancing our sales capabilities through an improved digital presence and the use of data-driven marketing automation tools.
Maintaining profitability through pricing mechanisms to mitigate the impacts of ongoing supply chain disruptions and inflationary pressures while ensuring prices are market competitive.
Integrating recent acquisitions to further enhance our strategic position and accelerate long-term sales growth.
Driving operational excellence and executing sustainable efficiency gains within our selling, general and administrative structures and within our global operations including insourcing of critical products and manufacturing activities while reducing our environmental footprint.
Enhancing our high-performance culture, which rewards execution and respects diversity, to elevate employee engagement and improve recruitment and retention practices in order to drive differential performance and execute our strategy.
Macroeconomic Conditions and Trends
The Company's operations and financial performance are subject to the risks and uncertainties inherent in the global economic environment, including inflationary pressures, supply chain disruptions, and other macroeconomic challenges. These pressures may impact the Company's business, financial condition and results of operations as the global economic outlook remains uncertain.
18

Table of Contents
In recent months, the U.S. government introduced incremental import tariffs on goods imported into the U.S. from numerous countries, triggering reciprocal tariffs and other actions from many trading partners on goods exported from the U.S. Trade policies of the U.S. and other countries, including China, are complex and rapidly evolving. Our strategy of manufacturing products near the point of sale reduces our overall exposure to tariffs, though certain sourced inputs and manufactured items remain subject to incremental tariffs. Our business has incurred, and expects to continue to incur, additional costs as it relates to these incremental tariffs for the remainder of fiscal 2025 and the foreseeable future. The Company has taken and will continue to take action to mitigate inflationary pressures caused by the incremental tariffs through a combination of targeted price increases and surcharges, strategic sourcing adjustments, product portfolio optimization, as well as our ongoing efforts to drive sustainable efficiency gains in our operations and administrative structures.
Notwithstanding the fluid situation relating to tariffs, we believe our financial strength positions us well to continue investing in acquisitions and organic growth opportunities, such as expanded sales channels, marketing programs, and research and development (“R&D”). We remain focused on driving sustainable efficiency gains and automation across our operations and selling, general and administrative (“SG&A”) functions, while also returning capital to our shareholders through dividends and share repurchases. At April 30, 2025, we had cash of $152.2 million, as well as a credit agreement with $195.2 million available for future borrowing, which can be increased to $1,085.2 million at the Company's option and subject to certain conditions, for total available liquidity of $1,237.4 million.
We believe that our financial resources and liquidity levels, including the undrawn portion of our credit agreement and our ability to increase that credit line as necessary, are sufficient to support the execution of our growth strategy and to manage the impact of economic or geopolitical events that could potentially reduce sales, net income, or cash provided by operating activities. Refer to Risk Factors, included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended July 31, 2024, for further discussion of the possible impact of global economic or geopolitical events on our business.

Results of Operations
The comparability of the operating results for the three and nine months ended April 30, 2025 compared to the same periods in the prior year have been impacted by the acquisitions of Gravotech on August 1, 2024, AB&R on October 1, 2024 and Microfluidic Solutions on April 1, 2025. The operating results of Gravotech, AB&R and Microfluidic Solutions have been included since their acquisition dates. Gravotech has been included in both reportable segments, and AB&R and Microfluidic Solutions have been included in the Americas & Asia reportable segment. The comparability of the year-to-date operating results of the Americas & Asia segment has also been impacted by the divestiture of a non-core business in October 2023.
A comparison of results of operating income for the three and nine months ended April 30, 2025 and 2024, is as follows:
Three months ended April 30,Nine months ended April 30,
(Dollars in thousands)2025% Sales2024% Sales2025% Sales2024% Sales
Net sales$382,590 $343,384 $1,116,330 $997,991 
Gross margin195,059 51.0 %177,027 51.6 %560,591 50.2 %510,829 51.2 %
Operating expenses:
Research and development19,191 5.0 %17,681 5.1 %56,835 5.1 %50,215 5.0 %
Selling, general and administrative108,678 28.4 %95,803 27.9 %326,410 29.2 %283,415 28.4 %
Total operating expenses127,869 33.4 %113,484 33.0 %383,245 34.3 %333,630 33.4 %
Operating income$67,190 17.6 %$63,543 18.5 %$177,346 15.9 %$177,199 17.8 %
References in this Form 10-Q to “organic sales” refer to sales calculated in accordance with GAAP, excluding the impact of foreign currency translation, sales recorded from acquired companies prior to the first anniversary date of their acquisition, and sales recorded from divested companies up to the first anniversary of their divestiture. The Company's organic sales disclosures exclude the effects of foreign currency translation as foreign currency translation is subject to volatility that can obscure underlying business trends. Management believes that the non-GAAP financial measure of organic sales is meaningful to investors as it provides them with useful information to aid in identifying underlying sales trends in our businesses and facilitating comparisons of our sales performance with prior periods.
Net sales for the three months ended April 30, 2025 increased 11.4% to $382.6 million compared to $343.4 million in the same period in the prior year. The increase consisted of organic sales growth of 1.6% and sales growth from acquisitions of 10.5%, which was partially offset by a decrease from foreign currency translation of 0.7%. Organic sales growth of 5.4% in the Americas & Asia segment was partially offset by an organic sales decline of 5.4% in the Europe & Australia segment during the three months ended April 30, 2025 compared to the same period in the prior year.
19

Table of Contents
Net sales for the nine months ended April 30, 2025 increased 11.9% to $1,116.3 million compared to $998.0 million in the same period in the prior year. The increase consisted of organic sales growth of 2.6% and sales growth from acquisitions of 10.2%, partially offset by a decrease from foreign currency translation of 0.5% and a decrease of 0.4% due to a divestiture. Organic sales grew 5.0% in the Americas & Asia segment, while organic sales declined 1.9% in the Europe & Australia segment during the nine months ended April 30, 2025 compared to the same period in the prior year.
Gross margin increased 10.2% to $195.1 million in the three months ended April 30, 2025 compared to $177.0 million in the same period in the prior year. As a percentage of net sales, gross margin decreased to 51.0% from 51.6% in the three-month period. Gross margin increased 9.7% to $560.6 million in the nine months ended April 30, 2025 compared to $510.8 million in the same period in the prior year. As a percentage of net sales, gross margin decreased to 50.2% from 51.2% in the nine-month period. The decrease in gross margin as a percentage of net sales during the three-month period was primarily due to the impact of incremental tariffs, primarily on goods imported to the U.S. from China, and $1.1 million of facility closure and other reorganization costs, which were partially offset by organic sales growth in higher gross margin product lines. The decrease in gross margin as a percentage of net sales during the nine months ended April 30, 2025 was primarily due to a non-recurring increase in cost of goods sold of $4.1 million related to the fair value adjustment to inventory from acquisitions, facility closure and other reorganization costs of $3.0 million, as well as the impact of incremental tariffs, which were partially offset by organic sales growth in higher gross margin product lines.
R&D expenses increased 8.5% to $19.2 million in the three months ended April 30, 2025 compared to $17.7 million in the same period in the prior year. As a percentage of net sales, R&D expenses decreased to 5.0% in the three-month period compared to 5.1% in the same period in the prior year. R&D expenses increased 13.2% to $56.8 million in the nine months ended April 30, 2025 compared to $50.2 million in the same period in the prior year. As a percentage of net sales, R&D expenses increased to 5.1% from 5.0% in the nine-month period. The increase in R&D spending was primarily due to the acquisition of Gravotech, and, to a lesser extent, an increase in R&D headcount within the Company's organic business. The Company remains committed to investing in new product development to drive long-term organic sales growth. Investments in new printing systems, materials and new product development within recent acquisitions are the primary focus of R&D expenditures in fiscal 2025.
SG&A expenses include selling and administrative costs directly attributed to the Americas & Asia and Europe & Australia segments, as well as certain other corporate administrative expenses including finance, information technology, human resources and other administrative expenses. SG&A expenses increased 13.4% to $108.7 million in the three months ended April 30, 2025 compared to $95.8 million in the same period in the prior year. As a percentage of sales, SG&A expenses increased to 28.4% from 27.9% in the three-month period. SG&A expenses increased 15.2% to $326.4 million for the nine months ended April 30, 2025 compared to $283.4 million in the same period in the prior year. As a percentage of net sales, SG&A expenses increased to 29.2% from 28.4% in the nine-month period. The increase in SG&A expenses during the three and nine months ended April 30, 2025 was primarily due to increased headcount and other selling-related costs from acquisitions, including incremental amortization expense from the acquired intangible assets. Amortization expense increased $2.4 million and $7.1 million during the three and nine months ended April 30, 2025 compared to the same periods in the prior year. SG&A expenses during the three and nine months ended April 30, 2025 also include facility closure and other reorganization costs of $2.8 million and $6.6 million, respectively. SG&A expenses during the nine months ended April 30, 2025 also include non-recurring acquisition-related costs and other expenses of $1.0 million.
Operating income increased 5.7% to $67.2 million and increased 0.1% to $177.3 million in the three and nine months ended April 30, 2025, respectively, compared to $63.5 million and $177.2 million in the same periods in the prior year. The increase in operating income in both the three and nine-month periods was primarily due to organic sales growth in higher gross margin product lines, which was partially offset by non-recurring acquisition-related costs and incremental amortization expense related to acquired businesses, as well as facility closure and other reorganization costs.
20

Table of Contents
OPERATING INCOME TO NET INCOME
Three months ended April 30,Nine months ended April 30,
(Dollars in thousands)2025% Sales2024% Sales2025% Sales2024% Sales
Operating income $67,190 17.6 %$63,543 18.5 %$177,346 15.9 %$177,199 17.8 %
Other (expense) income:
Investment and other (expense) income(509)(0.1)%1,596 0.5 %2,850 0.3 %4,718 0.5 %
Interest expense(936)(0.2)%(728)(0.2)%(3,604)(0.3)%(2,284)(0.2)%
Income before income taxes65,745 17.2 %64,411 18.8 %176,592 15.8 %179,633 18.0 %
Income tax expense13,482 3.5 %13,521 3.9 %37,212 3.3 %37,874 3.8 %
Net income$52,263 13.7 %$50,890 14.8 %$139,380 12.5 %$141,759 14.2 %
Investment and other (expense) income was a net expense of $0.5 million in the three months ended April 30, 2025 compared to net investment income of $1.6 million in the same period in the prior year. Investment and other (expense) income decreased to $2.9 million of net investment income in the nine months ended April 30, 2025 compared to $4.7 million in the same period in the prior year. The change in investment and other (expense) income during both the three and nine-month periods was primarily due to the change in market value of securities held in deferred compensation plans.
Interest expense increased to $0.9 million and $3.6 million for the three and nine months ended April 30, 2025, respectively, compared to $0.7 million and $2.3 million in the same periods in the prior year. The increase in interest expense was primarily due to an increase in outstanding borrowings on the Company's credit agreement to fund acquisitions, which was partially offset by a decrease in the weighted average interest rate compared to the same periods in the prior year.
The Company's income tax rate was 20.5% and 21.0% for the three months ended April 30, 2025 and 2024, respectively, and the income tax rate was 21.1% for both of the nine-month periods ended April 30, 2025 and 2024. The Company expects its ongoing annual income tax rate to be approximately 21% based on its current global business mix and based on tax laws and statutory rates currently in effect.
Business Segment Operating Results
The Company evaluates short-term segment performance based on segment profit and customer sales. Interest expense, investment and other income, income tax expense, and certain corporate administrative expenses are excluded when evaluating segment performance.
21

Table of Contents
The following is a summary of segment information for the three and nine months ended April 30, 2025 and 2024:
Three months ended April 30,Nine months ended April 30,
2025202420252024
SALES GROWTH INFORMATION
Americas & Asia
Organic5.4 %4.5 %5.0 %3.0 %
Acquisitions8.6 %— %7.9 %— %
Currency(1.1)%(0.1)%(1.0)%— %
Divestiture— %(3.5)%(0.5)%(3.5)%
Total12.9 %0.9 %11.4 %(0.5)%
Europe & Australia
Organic(5.4)%4.4 %(1.9)%2.8 %
Acquisitions14.2 %— %14.2 %— %
Currency(0.1)%(0.6)%(0.1)%1.9 %
Total8.7 %3.8 %12.8 %4.7 %
Total Company
Organic1.6 %4.5 %2.6 %3.0 %
Acquisitions10.5 %— %10.2 %— %
Currency(0.7)%(0.3)%(0.5)%0.6 %
Divestiture— %(2.3)%(0.4)%(2.4)%
Total11.4 %1.9 %11.9 %1.2 %
SEGMENT PROFIT
Americas & Asia$57,164 $49,697 $158,148 $143,489 
Europe & Australia17,478 19,537 41,872 51,335 
Total$74,642 $69,234 $200,020 $194,824 
SEGMENT PROFIT AS A PERCENT OF NET SALES
Americas & Asia22.5 %22.1 %21.6 %21.8 %
Europe & Australia13.6 %16.5 %10.9 %15.1 %
Total19.5 %20.2 %17.9 %19.5 %
Americas & Asia
Americas & Asia net sales increased 12.9% to $253.7 million in the three months ended April 30, 2025 compared to $224.8 million in the same period in the prior year, which consisted of organic sales growth of 5.4% and sales growth from acquisitions of 8.6%, which were partially offset by a decrease from foreign currency translation of 1.1%. Americas & Asia net sales increased 11.4% to $732.9 million in the nine months ended April 30, 2025 compared to $658.0 million in the same period in the prior year, which consisted of organic sales growth of 5.0% and sales growth from acquisitions of 7.9%, which were partially offset by a decrease from foreign currency translation of 1.0% and a decrease due to a divestiture of 0.5%.
Organic sales in the Americas increased in the low-single digits in both the three and nine months ended April 30, 2025 compared to the same periods in the prior year. Organic sales growth in both the three and nine-month periods was driven by growth in the wire identification, safety and facility identification and product identification product lines. Organic sales growth was partially offset by an organic sales decline in the people identification product line in the three months ended April 30, 2025, and an organic sales decline in the healthcare identification product line in the nine months ended April 30, 2025.
Organic sales in Asia increased approximately 23% in the three months ended April 30, 2025, and increased approximately 13% in the nine months ended April 30, 2025 compared to the same periods in the prior year. The organic sales increase in the three-month period was realized throughout Asia, which included a return to organic sales growth in China. Organic sales growth in the nine-month period resulted from growth throughout Asia, partially offset by flat organic sales in China. Organic sales in both the three and nine-month periods were driven by growth in all major product lines, with particularly strong growth in the product identification and safety and facility identification product lines.
Americas & Asia segment profit increased 15.0% to $57.2 million in the three months ended April 30, 2025 compared to $49.7 million in the same period in the prior year. Segment profit increased 10.2% to $158.1 million in the nine months ended April 30, 2025 compared to $143.5 million in the same period in the prior year. As a percentage of net sales, segment profit increased to 22.5% from 22.1% in the three-month period and segment profit decreased to 21.6% from 21.8% in the nine-month period ended April 30, 2025 compared to the same periods in the prior year. The decrease in segment profit as a percentage of
22

Table of Contents
sales was primarily due to costs associated with the closure of two facilities, incremental amortization from acquired businesses and purchase accounting adjustments during the nine-month period, which was partially offset by increased profit from organic sales growth.
Europe & Australia
Europe & Australia net sales increased 8.7% to $128.9 million in the three months ended April 30, 2025 compared to $118.6 million in the same period in the prior year, which consisted of sales growth from acquisitions of 14.2% that was partially offset by an organic sales decline of 5.4% and a decrease from foreign currency translation of 0.1%. Europe & Australia net sales increased 12.8% to $383.4 million in the nine months ended April 30, 2025 compared to $340.0 million in the same period in the prior year, which consisted of sales growth from acquisitions of 14.8%, which was partially offset by an organic sales decline of 1.9% and a decrease from foreign currency translation of 0.1%.
Organic sales in Europe declined in the mid-single digits in the three months ended April 30, 2025 and declined in the low-single digits in the nine months ended April 30, 2025 compared to the same periods in the prior year. Organic sales growth in the wire identification product line was more than offset by an organic sales decline in the product identification, safety and facility identification and people identification product lines during both the three and nine-month periods.
Organic sales in Australia declined in the mid-single digits in both the three and nine months ended April 30, 2025 compared to the same periods in the prior year. The organic sales decline was primarily driven by a decrease in volume in the safety and facility and wire identification product lines.
Europe & Australia segment profit decreased 10.5% to $17.5 million in the three months ended April 30, 2025 compared to $19.5 million in the same period in the prior year. Segment profit decreased 18.4% to $41.9 million in the nine months ended April 30, 2025 compared to $51.3 million in the same period in the prior year. As a percentage of net sales, segment profit decreased to 13.6% from 16.5% for the three-month period and segment profit decreased to 10.9% from 15.1% for the nine-month period ended April 30, 2025, compared to the same periods in the prior year. The decrease in segment profit and segment profit as a percentage of sales was primarily due to incremental amortization from acquired businesses, purchase accounting adjustments and reorganization costs in order to streamline our operating structure.
Liquidity and Capital Resources
The Company's cash balances are generated and held in numerous locations throughout the world. At April 30, 2025, 95% of the Company's cash and cash equivalents were held outside the United States. The Company's organic and inorganic growth has historically been funded by a combination of cash provided by operating activities and debt financing. The Company believes that its cash flow from operating activities and its borrowing capacity are sufficient to fund its anticipated requirements for working capital, capital expenditures, research and development, common stock repurchases, and dividend payments for the next 12 months. Although the Company believes these sources of cash are currently sufficient to fund domestic operations, annual cash needs could require repatriation of cash to the U.S. from foreign jurisdictions, which may result in additional tax payments.
Cash Flows
Cash and cash equivalents were $152.2 million at April 30, 2025, a decrease of $98.0 million from July 31, 2024. The significant changes were as follows:
 Nine months ended April 30,
(Dollars in thousands)20252024
Net cash flow provided by (used in):
Operating activities$122,874 $171,094 
Investing activities(165,079)(70,331)
Financing activities(52,077)(88,989)
Effect of exchange rate changes on cash(3,682)(2,848)
Net (decrease) increase in cash and cash equivalents$(97,964)$8,926 
Net cash provided by operating activities was $122.9 million in the nine months ended April 30, 2025, compared to $171.1 million in the same period of the prior year. The decrease in cash provided by operating activities was primarily due to changes in working capital. Increased cash outflows related to inventory were primarily due to new product launches and the timing of facility moves during the nine months ended April 30, 2025. Additionally, higher cash outflows related to accounts payable in the current year were primarily driven by normalization of outstanding payables from acquired businesses.
23

Table of Contents
Net cash used in investing activities was $165.1 million in the nine months ended April 30, 2025, which primarily consisted of the acquisition of businesses of $147.2 million and capital expenditures of $18.7 million. Net cash used in investing activities was $70.3 million in the nine months ended April 30, 2024, which primarily consisted of capital expenditures including the purchase of a previously leased facility in Mexico and facility construction costs in Belgium.
Net cash used in financing activities was $52.1 million in the nine months ended April 30, 2025 compared to $89.0 million in the same period in the prior year. The decrease in cash used in financing activities was primarily due to a decline in share repurchases compared to the same period in the prior year.
Material Cash Requirements
Our material cash requirements for known contractual obligations include capital expenditures, borrowings on our credit agreement and lease obligations. We believe that net cash provided by operating activities will continue to be adequate to meet our liquidity and capital needs for these items over the next 12 months and in the long-term beyond the next 12 months. We also have cash requirements for purchase orders and contracts for the purchase of inventory and other goods and services, which are based on current and anticipated customer needs and are fulfilled by our suppliers within short time horizons. We do not have significant agreements for the purchase of inventory or other goods or services specifying minimum order quantities. In addition, we may have liabilities for uncertain tax positions, but we do not believe that the cash requirements to meet any of these liabilities will be material.
Credit Agreement
On August 1, 2019, the Company and certain of its subsidiaries entered into an unsecured $200 million multi-currency credit agreement with a group of five banks.
On November 14, 2022, the Company and certain of its subsidiaries entered into a second amendment to the credit agreement to, among other items, (a) increase the lending commitments by $100 million for total lending commitments of $300 million, (b) extend the final maturity date to November 14, 2027, (c) increase the interest rate on certain borrowings by 0.125%, and (d) increase the available amount under the credit agreement, at the Company's option and subject to certain conditions, from $300 million up to (i) an amount equal to the incremental borrowing necessary to bring the Company's consolidated net debt-to-EBITDA ratio as defined in the credit agreement to 2.5 to 1.0 plus (ii) $200 million.
On October 10, 2024, the Company and certain of its subsidiaries entered into a Third Amendment to Credit Agreement (“Amendment No. 3”) with a group of six banks, which amended the original credit agreement dated August 1, 2019. Amendment No. 3 amended the credit agreement to, among other things, change the applicable benchmark under the credit agreement for borrowings denominated in Canadian Dollars from the Canadian Dollar Offered Rate (“CDOR”) to the adjusted Term Canadian Overnight Repo Rate Average Rate (“CORRA”). Borrowings under Amendment No. 3 are unsecured and are guaranteed by certain of the Company's domestic subsidiaries.
As of April 30, 2025, the outstanding balance on the Company's credit agreement was $102.8 million. The maximum amount outstanding on the credit agreement during the nine months ended April 30, 2025 was $144.8 million. As of April 30, 2025, the U.S. dollar-denominated borrowings of $42.0 million bear interest at 5.3%; the Euro-denominated borrowings of €44.0 million bear interest at 3.2%; and the British Pound-denominated borrowings of £8.0 million bear interest at 5.3%. The Company had letters of credit outstanding under the credit agreement of $2.0 million as of April 30, 2025, and there was $195.2 million available for future borrowing, which can be increased to $1,085.2 million at the Company's option, subject to certain conditions. The credit agreement has a final maturity date of November 14, 2027. As such, borrowings were classified as long-term on the condensed consolidated balance sheets.
Covenant Compliance
The Company's credit agreement requires it to maintain certain financial covenants, including a ratio of debt to the trailing twelve months EBITDA, as defined in the debt agreements, of not more than a 3.5 to 1.0 ratio (leverage ratio) and the trailing twelve months EBITDA to interest expense of not less than a 3.0 to 1.0 ratio (interest expense coverage). As of April 30, 2025, the Company was in compliance with these financial covenants, with a ratio of debt to EBITDA, as defined by the agreements, equal to 0.3 to 1.0 and the interest expense coverage ratio equal to 71.5 to 1.0.
Forward-Looking Statements
In this quarterly report on Form 10-Q, statements that are not reported financial results or other historic information are “forward-looking statements.” These forward-looking statements relate to, among other things, the Company's future financial position, business strategy, targets, projected sales, costs, income, capital expenditures, debt levels and cash flows, and plans and objectives of management for future operations.
24

Table of Contents
The use of words such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “should,” “project” or “plan” or similar terminology are generally intended to identify forward-looking statements. These forward-looking statements by their nature address matters that are, to different degrees, uncertain and are subject to risks, assumptions, and other factors, some of which are beyond Brady's control, that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For Brady, uncertainties arise from:
Increased cost of materials, labor, material shortages and supply chain disruptions, including as a result of tariffs or other impacts of the global trade environment
Decreased demand for the Company's products
Ability to compete effectively or to successfully execute the Company's strategy
Ability to develop technologically advanced products that meet customer demands
Ability to identify, integrate, and grow acquired companies, and to manage contingent liabilities from divested businesses
Difficulties in protecting websites, networks, and systems against security breaches and difficulties in preventing phishing attacks, social engineering or malicious break-ins
Risks associated with the loss of key employees
Global climate change and environmental regulations
Litigation, including product liability claims
Foreign currency fluctuations
Changes in tax legislation and tax rates
Potential write-offs of goodwill and other intangible assets
Differing interests of voting and non-voting shareholders and changes in the regulatory and business environment around dual-class voting structures
Numerous other matters of national, regional and global scale, including major public health crises and government responses thereto and those of a political, economic, business, competitive, and regulatory nature contained from time to time in Brady's U.S. Securities and Exchange Commission (“SEC”) filings, including, but not limited to, those factors listed in the “Risk Factors” section within Item 1A of Part I of Brady's Form 10-K for the year ended July 31, 2024.
These uncertainties may cause Brady's actual future results to be materially different than those expressed in its forward-looking statements. Brady does not undertake to update its forward-looking statements except as required by law.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Refer to the Company’s annual report on Form 10-K for the year ended July 31, 2024. There has been no material change in this information since the 2024 Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES
Brady Corporation maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed by the Company in the reports filed by the Company under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports the Company files under the Exchange Act is accumulated and communicated to the Company’s management, including the Company’s principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company carried out an evaluation, under the supervision and with the participation of its management, including its President and Chief Executive Officer (the “Chief Executive Officer”) and its Chief Financial Officer, Chief Accounting Officer and Treasurer (the “Chief Financial Officer”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 of the Exchange Act. Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of the end of the period covered by this report.
There were no changes in the Company's internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the Company's most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
25

Table of Contents
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
The information set forth in Note M, "Contingencies" included in this Quarterly Report on Form 10-Q is incorporated herein by reference.

ITEM 1A. RISK FACTORS
The Company’s business, results of operations, financial condition, and cash flows are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” of Company’s Annual Report on Form 10-K for the year ended July 31, 2024. There have been no material changes from the risk factors set forth in the 2024 Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The Company maintains a share repurchase program for the Company's Class A Nonvoting Common Stock. The program may be implemented by purchasing shares in the open market or in privately negotiated transactions, with repurchased shares available for use in connection with the Company's stock-based plans and for other corporate purposes.
On September 4, 2024, the Company's Board of Directors authorized an increase in the Company's share repurchase program, authorizing the repurchase of an additional $100.0 million of the Company's Class A Nonvoting Common Stock, which expanded upon the Company's prior authorization for a total authorized amount of $137.8 million. The share repurchase program may be implemented from time to time on the open market or in privately negotiated transactions and has no expiration date. As of April 30, 2025, there was $104.6 million worth of repurchase authority remaining pursuant to the existing share repurchase program.
The following table provides information with respect to the purchases by the Company of Class A Nonvoting Common Stock during the three months ended April 30, 2025:
PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
(Dollars in Thousands)
February 1, 2025 - February 28, 202545,148 $72.31 45,148 $134,524 
March 1, 2025 - March 31, 2025264,170 70.59 264,170 115,877 
April 1, 2025 - April 30, 2025166,760 67.43 166,760 104,633 
Total476,078 $69.64 476,078 $104,633 

ITEM 5. OTHER INFORMATION
During the three months ended April 30, 2025, no director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is identified in Item 408(a) of Regulation S-K.
26

Table of Contents
ITEM 6. EXHIBITS
Exhibit No.Exhibit Description
31.1
31.2
32.1
32.2
101.INSInline XBRL Instance Document (The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.)
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Label Linkbase Document
104Cover Page Interactive Data File (Formatted as Inline XBRL contained in Exhibit 101)
27

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
      BRADY CORPORATION
Date: May 16, 2025 /s/ RUSSELL R. SHALLER
 Russell R. Shaller
 President and Chief Executive Officer
 (Principal Executive Officer)
Date: May 16, 2025   /s/ ANN E. THORNTON
   Ann E. Thornton
   Chief Financial Officer, Chief Accounting Officer and Treasurer
   (Principal Financial Officer and Principal Accounting Officer)

28